Dietary supplement found to improve concentration levels

The PROFITH CTS-977 research group from the University of Granada (UGR) has tested the effects of a multi-ingredient dietary nootropic on concentration levels and cognitive performance. Nootropics are cognitive enhancers that have traditionally been used in the treatment of cognitive pathologies. Leading this study was Lucas Jurado Fasoli—a researcher from the Scientific Unit of Excellence in Exercise, Nutrition and Health […]

Continue reading »

Fatty liver is increasingly the cause of liver cell cancer

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. In Germany, there are currently around 9,000 new HCC diagnoses per year, and almost 8,000 people affected do not survive the disease. Before the tumor develops in the liver, the organ is often already damaged by chronic inflammation. The traditional causes of chronic liver damage include, in particular, infections […]

Continue reading »

Artificial intelligence-based algorithm predicts major adverse kidney events after hospitalization

Serious kidney-related complications—or major adverse kidney events—are common after hospitalization for various medical problems. Investigators have now developed and validated an artificial intelligence-based algorithm to predict a patient’s risk of major adverse kidney events within 90 days of hospital discharge. The research will be presented at ASN Kidney Week 2022 November 3-November 6. The scientists developed and validated their algorithm […]

Continue reading »

Why New Zealand must consider restricting alcohol sponsorship of broadcast sports as part of a wider law reform

For those concerned about the public health impacts of alcohol, the government’s recent policy announcement was perhaps a little “glass half empty” to be cause for outright celebration. As Justice Minister Kiri Allan outlined, the government’s review of alcohol laws will start by implementing only one of the reforms proposed in Green MP Chlöe Swarbrick’s Sale and Supply of Alcohol […]

Continue reading »

Oral Steroid Safely Treats IgA Nephropathy: Trial Published

Patients with immunoglobulin A (IgA) nephropathy showed clinically meaningful improvements in several measures of renal function after 9 months of treatment with a delayed-release formulation of the oral glucocorticoid budesonide, Nefecon, in a pivotal trial. The newly published findings “support Nefecon as the first disease-modifying therapy approved for patients with primary IgA nephropathy at risk of end-stage kidney disease,” write […]

Continue reading »
1 305 306 307 308 309 1,322